A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original - Primary - Respiratory - NCCTG-N0026
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010 Manuscript - Secondary-not-in-original - Primary - Respiratory - N0026
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original - Primary - GI - NCCTG-N9741
Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014 Manuscript - Secondary-not-in-original - Primary - Respiratory - CALGB-30203
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials An, Ming-Wen , Tang, Jun , Grothey, Axel , Sargent, Daniel J. ... - - Contemp Clin Trials Commun - 2019 Manuscript - Secondary-not-in-original - Primary - GI - A151817 , N0026 , N9741 , NCCTG-N9741
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018 Manuscript - Primary - Primary - Leukemia - CALGB-10404
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original - Comprehensive - GI - NCCTG-N0026 , NCCTG-N9741
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Health Outcome - NCCTG-N0392
A prospective economic analysis of Canadian Cancer Trials Group CLC.2/Alliance A041202: A randomized phase III comparison of bendamustine-rituximab versus ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia Cheung, Matthew C. , Mittmann, Nicole , Owen, Carolyn ... - ASH - Blood - 2020 Abstract - Secondary-not-in-original - Primary - Leukemia - A041202
Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-N0723
A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Respiratory - NCCTG-N0528
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Respiratory - NCCTG-N0821
A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261 Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010 Manuscript - Primary - Primary - Respiratory - N0326
A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528 Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013 Manuscript - Primary - Primary - Respiratory - NCCTG-N0528
NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014 Manuscript - Primary - Primary - Respiratory - NCCTG-N0821
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - - Blood - 2020 Manuscript - Secondary-not-in-original - Primary - Leuk Corr Sci - CALGB-10603
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original - Primary - Leukemia - Z901101
Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC) Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Respiratory - ACOSOG-Z4032
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer Fernando, Hiran C. , Landreneau, Rodney J. , Mandrekar, Sumithra J. ... - - J. Clin. Oncol - 2014 Manuscript - Primary - Primary - Respiratory - ACOSOG-Z4032
The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial Fernando, Hiran C , Landreneau, Rodney J , Mandrekar, Sumithra J ... - - J Thorac Cardiovasc Surg - 2011 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4032
Analysis of longitudinal quality of life data in high-risk operable patients with lung cancer: Results from ACOSOG Z4032 (Alliance) a multicenter randomized trial Fernando, Hiran C , Landreneau, Rodney J , Mandrekar, Sumithra J ... - - J. Thorac. Cardiovasc. Surg. - 2015 Manuscript - Secondary - Primary - Health Outcome - ACOSOG-Z4032
Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary - Primary - Respiratory - N0424
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - N0424
Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Krook, J. E. , Kugler, J. W. , Kuross, S. A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - N0424
Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Respiratory - NCCTG-N0424
Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis Foster, N. R. , Renfro, L. A. , Schild, S. E. , Redman, M. W. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Meta-Analysis - Respiratory - Comprehensive , CALGB-9033 , CALGB-9732 , CALGB-30103 , NCCTG-862051 , NCCTG-892051 , NCCTG-932053 , ECOG-1500 , ECOG-7593 , JCOG-9511 , NCIC-BR4 , NCIC-BR8 , SWOG-S0124
Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Mandrekar, Sumithra J. , Schild, Steven E. ... - - Cancer - 2009 Manuscript - Secondary - Primary - Respiratory - N0424
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011 Manuscript - Primary - Primary - Respiratory - N0424
Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Foster, Nathan R. , Renfro, Lindsay A. , Schild, Steven E. ... - - J Thorac Oncol - 2015 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - CALGB-30103 , N0424 , NCCTG-932053
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. Garces, Yolanda I , Okuno, Scott H , Schild, Steven E ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007 Manuscript - Primary - Primary - Respiratory - N9923
ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early Stage Non–Small Cell Lung Cancer Govindan, Ramaswamy , Mandrekar, Sumithra J. , Gerber, David E. ... - - Clin. Cancer Res. - 2015 Manuscript - No-Endpoint - Trial-Description-Only - Respiratory - A151216
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation Hillman, S. L. , Mandrekar, S. J. , Bot, B. , Dematteo, R. P. ... - - J. Clin. Oncol. - 2010 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - ACOSOG-Z9001 , NCCTG-97-24-51
Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG). Hillman, SL , Sargent, DJ , Bot, BM , RP, DeMatteo , Perez, EA ... - ASCO - J Clin Oncol - 2007 Abstract - Secondary-not-in-original - Primary - GI - ACOSOG-Z9001
A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Huschka, Mashele M , Mandrekar, Sumithra J , Schaefer, Paul L ... - - Cancer - 2007 Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - N0021 , N0022 , NCCTG-95-20-53 , NCCTG-95-24-51 , NCCTG-95-24-52 , NCCTG-97-24-51 , NCCTG-98-24-52
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Johnson, Elizabeth A , Marks, Randolph S , Mandrekar, Sumithra J ... - - Lung Cancer - 2008 Manuscript - Primary - Primary - Respiratory - NCCTG-972451
Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC) Kent, M. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4032
Impact of Sublobar Resection on Pulmonary Function: Long-term Results from ACOSOG Z4032 (Alliance) Kent, Michael S. , Mandrekar, Sumithra J. , Landreneau, Rodney ... - - Ann. Thorac. Surg. - 2016 Manuscript - Secondary - Primary - Respiratory - ACOSOG-Z4032
A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032) Kent, Michael S. , Mandrekar, Sumithra J. , Landreneau, Rodney ... - - Ann. Thorac. Surg. - 2016 Manuscript - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4032
Impact of Sublobar Resection on pulmonary function; Long-term results from Z4032 (Alliance), a randomized phase III trial Kent, Michael , Fernando, Hiran C , Mandrekar, Sumithra ... - STSA - Ann Thoracic Surg - 2016 Abstract - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4032
Development of a Nomogram for Predicting Outcomes after Sublobar Resection for lung cancer; An Analysis from ACOSOG Z4032 (Alliance) a Randomized Trial Kent, Michael , Mandrekar, Sumithra , Landreneau, Rodney ... - AATS - - 2015 Abstract - Secondary-not-in-original - Primary - Respiratory - ACOSOG-Z4032
An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Larson, Richard A. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary - Primary - Leukemia - CALGB-10603
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Larson, Richard A , Mandrekar, Sumithra J , Huebner, Lucas J ... - - Leukemia - 2021 Manuscript - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Application of multi-state models in cancer clinical trials Le-Rademacher, Jennifer G , Peterson, Ryan A , Therneau, Terry M ... - - Clin Trials - 2018 Manuscript - No-Endpoint - Other - Leukemia - A151732 , CALGB-10603
Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. Le-Rademacher, Jennifer , Lopez, Camden , Wolfe, Eric ... - - J Cachexia Sarcopenia Muscle - 2020 Manuscript - Secondary-not-in-original - Primary - Health Outcome - A151822
Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation Mandrekar, S. J. , Hillman, S. L. , Ziegler, K. L. Allen ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - N0424
Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: a joint North Center Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation Mandrekar, S. J. , Qi, Y. , Allen-Ziegler, K. , Hillman, S. L. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary - Primary - Respiratory - N0424
Impact of the Algorithm for Declaring Exact Progression Data on Progression-Free Survival Estimates in Advanced Lung Cancer Mandrekar, S. , Hillman, S. , Jatoi, A. , Jett, J. , Schild, S. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Respiratory - N0424
Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer Mandrekar, Sumithra J. , Foster, Nathan R. , Qi, Yingwei ... - ASCO - J. Clin. Oncol. - 2012 Abstract - No-Endpoint - Comprehensive - Respiratory - N0424
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data Mauguen, A. , Pignon, J. P. , Burdett, S. , Domerg, C. , Fisher, D. ... - - Lancet Oncol. - 2013 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - CALGB-8831 , CALGB-9310 , CALGB-9633 , NCCTG-892052 , NCCTG-902451 , NCCTG-942452
A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study Molina, J. R. , Dy, G. K. , Foster, N. R. , Ziegler, Allen ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary - Primary - Respiratory - N0626
A randomized double-blinded phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG N0923 (Alliance) Study Molina, J. R. , Mandrekar, S. J. , Dy, G. , Aubry, M. C. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Respiratory - N0923
A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study Molina, J. R. , Mandrekar, S. J. , Ziegler, K. L. Allen ... - - J Thorac Oncol - 2009 Abstract - Primary - Primary - Respiratory - NCCTG-N0623
Adjuvant targeted therapy following standard adjuvant therapy for resected NSCLC: An initial report from ALCHEMIST (Alliance A151216) Oxnard, Geoffrey R. , Mandrekar, Sumithra , Hillman, Shauna ... - IASLC (WCLC) - J Thorac Oncol - 2018 Abstract - No-Endpoint - Preliminary - Respiratory - A151216
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance) Parikh, Kaushal , Mandrekar, Sumithra J. , Allen‐Ziegler, Katie ... - - Oncologist - 2020 Manuscript - Primary - Primary - Respiratory - NCCTG-N0623
Incidence of bleeding and thrombosis among elderly patients undergoing systemic chemotherapy in advanced non-small cell lung cancer: An analysis of North Central Cancer Treatment Group trials Qi, Y. , Dy, G. K. , Nelson, G. D. , Schild, S. E. , Mandrekar, S. J. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Respiratory - N0424
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer Qi, Y. , Ziegler, K. L. Allen , Hillman, S. L. , Redman, M. W. ... - - Cancer - 2012 Manuscript - Secondary-not-in-original - Comprehensive - Respiratory - N0022 , N0026 , N0222 , N0323 , N0326 , N0426 , N0528 , N0626 , N0821 , N9921
Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Qi, Yingwei , Schild, Steven E. , Mandrekar, Sumithra J. ... - - J Thorac Oncol - 2009 Manuscript - Secondary - Primary - Respiratory - N0424
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Reungwetwattana, Thanyanan , Molina, Julian R ... - - J Thorac Oncol - 2012 Manuscript - Primary - Primary - Respiratory - N0323
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance) Roboz, Gail J. , Mandrekar, Sumithra J. , Desai, Pinkal ... - - Blood Adv - 2018 Manuscript - Primary - Primary - Leukemia - CALGB-11002
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia Ruppert, A S , Yin, J , Davidian, M , Tsiatis, A A , Byrd, J C ... - - Ann. Oncol - 2019 Manuscript - No-Endpoint - Other - Leukemia - A041202
A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance) Ruppert, Amy S. , Byrd, John C. , Heerema, Nyla A. , Smith, Mitchell ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary - Primary - Leukemia - CALGB-10404
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202 Ruppert, Amy S. , Mandrekar, Sumithra J. , Booth, Allison M ... - ASCO - JCO - 2020 Abstract - Secondary-not-in-original - Primary - Leukemia - A041202
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high risk resected NSCLC (Alliance) Sands, Jacob , Oxnard, Geoffrey R. , Kozono, David ... - ASCO - J Clin Oncol - 2020 Abstract - No-Endpoint - Trial-Description-Only - Respiratory - A081105 , A151216 , A081801
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. Schenk, Erin L , Mandrekar, Sumithra J , Dy, Grace K ... - - J Thorac Oncol - 2020 Manuscript - Primary - Primary - Respiratory - N0923
Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Schild, S. E. , Qi, Y. , Tan, A. D. , Mandrekar, S. J. , Adjei, A. A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary - Primary - Respiratory - NCCTG-N0424
The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC) Schild, S. , Mandrekar, S. , Jatoi, A. , Mcginnis, W. , Stella, P. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original - Comprehensive - Respiratory - NCCTG-94-24-52 , NCCTG-90-24-51
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Schild, Steven E , Mandrekar, Sumithra J , Jatoi, Aminah ... - - Cancer - 2007 Manuscript - Secondary-not-in-original - Meta-Analysis - Respiratory - NCCTG-90-24-51 , NCCTG-94-24-52
An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia Stock, Wendy , Diouf, Barthelemy , Crews, Kristine R. , Pei, Deqing ... - - Clin. Pharmacol. Ther. - 2017 Manuscript - Secondary-not-in-original - Meta-Analysis - Leukemia - CALGB-10102 , CALGB-10403 , CALGB-19802 , CALGB-9862
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation Stone, Richard M. , Mandrekar, Sumithra J. , Sanford, Ben L. ... - - N. Engl. J. Med. - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-10603
The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original - Primary - Leukemia - CALGB-10603
Midostaurin v Placebo plus Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation and Maintenance Therapy in Newly Diagnosed Acute Myeloid Leukemia ( AML) Patients ( pts) age 18-60 with FLT3 mutations: An International Prospective Randomized Placebo-Controlled Double-Blind Trial (CALGB 10603 [Alliance]) Stone, Richard M. , Mandrekar, Sumithra , Sanford, Ben L ... - ASH - Blood - 2015 Abstract - Secondary - Primary - Leukemia - CALGB-10603
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001 Uy, Geoffrey L. , Mandrekar, Sumithra J. , Laumann, Kristina ... - - Blood Adv - 2017 Manuscript - Primary - Primary - Leukemia - CALGB-11001
Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults With FLT3-ITD Mutated AML (Alliance C11001). Uy, Geoffrey L. , Mandrekar, Sumithra , Laumann, Kristina ... - ASH - Blood - 2015 Abstract - Primary - Primary - Leukemia - CALGB-11001
Ibrutinib alone or in combination with rituximab produces superior progression free survival compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia: Results of Alliance A041202 Woyach, Jennifer A. , Ruppert, Amy S. , Heerema, Nyla ... - ASH - Blood - 2018 Abstract - Primary - Primary - Leukemia - A041202
Alliance A041702: A randomized phase III study of ibrutinib plus obinutuzumab versus ibrutinib plus venetoclax and obinutuzumab in untreated older patients (≥ 70 years of age) with chronic lymphocytic leukemia (CLL) Woyach, Jennifer A. , Ruppert, Amy S. , Perez, Gabriela ... - ASH - Blood. - 2019 Abstract - No-Endpoint - Trial-Description-Only - Leukemia - A041702
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. Woyach, Jennifer A , Ruppert, Amy S , Heerema, Nyla A ... - - N. Engl. J. Med. - 2018 Manuscript - Primary - Primary - Leukemia - A041202
Event-free survival as a surrogate endpoint for overall survival in previously untreated acute myeloid leukemia: An individual patient-level analysis of multiple randomized trials (Alliance A151614) Yin, Jun , LaPlant, Betsy , Storrick, Elizabeth , Uy, Geoffrey L. ... - ASH - Blood - 2018 Abstract - Primary - Comprehensive - Leukemia - A151614 , CALGB-10201 , E1900 , CALGB-10603 , S0106
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614) Yin, Jun , LaPlant, Betsy , Uy, Geoffrey L. , Marcucci, Guido ... - - Blood Adv - 2019 Manuscript - Primary - Primary - Leukemia - A151614 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-10801 , CALGB-11001
Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia Yin, Jun , Laplant, Betsy R. , Uy, Geoffrey L. , Marcucci, Guido ... - ASH - JAMA Oncol - 2016 Abstract - Primary - Primary - Leukemia - A151614 , CALGB-10201 , CALGB-10503 , CALGB-10603 , CALGB-10801 , CALGB-11001
A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321 Zhao, Yujie , Foster, Nathan R. , Meyers, Jeffrey P. ... - - J Thorac Oncol - 2015 Manuscript - Primary - Primary - Respiratory - NCCTG-N0321
